How Stopping a GLP-1 Affects Your Blood Sugar Levels
DiabetesType 2 Diabetes

Stopping GLP-1s? How Weight Regain Impacts Type 2 Diabetes

Stopping GLP-1s? How Weight Regain Impacts Type 2 Diabetes
iStock
By
Published on July 27, 2026
by
Add us on Google

GLP-1 receptor agonists like semaglutide (Ozempic) and tirzepatide (Mounjaro) have helped reshape type 2 diabetes treatment, partly because the medications work by helping people lose weight.

While these drugs are intended to be a long-term treatment, research shows that nearly half of people with type 2 diabetes stop taking the medication within one year, in part because of intolerable side effects and the high costs of medication.

 Nausea, vomiting, and fatigue can be common side effects; high costs can cause other people to discontinue the drugs.

The problem is, once you stop taking a GLP-1, you may experience more than just weight gain. You may also experience higher blood sugar levels, more insulin resistance, and other changes to your metabolic health, including an increased risk of heart disease and kidney damage.

How Weight Loss Can Improve Type 2 Diabetes

A big part of managing type 2 diabetes is maintaining a healthy body weight, which may include losing weight. As we lose visceral fat (the fat that sits deeper in the abdomen), inflammation and cellular damage also decreases, says Tracy Norfleet, MD, a board-certified internal medicine physician and obesity medicine specialist in St. Louis.

Even modest weight loss can lead to metabolic improvements such as:

  • Better Blood Sugar Control Losing at least 5 percent of your baseline body weight can help reduce blood glucose, says Dr. Norfleet. As visceral fat decreases, the body becomes more responsive to insulin, which allows glucose to move out of the bloodstream more efficiently, lowering A1C levels.

  • Improved Heart Health Blood pressure and triglyceride levels typically improve with weight loss, reducing the risk of heart disease, which is already elevated in people with type 2 diabetes.

  • Fewer Doses of Medication As insulin sensitivity improves and blood glucose stabilizes, many people can reduce or eliminate other glucose-lowering medications under their doctor's supervision.

  • Lower Levels of Inflammation Excess fat, particularly around the abdomen, drives chronic low-grade inflammation that worsens insulin resistance.

Is Weight Regain Inevitable When You Stop Taking a GLP-1?

It’s very likely that the pounds will come back. Some research shows that, after stopping a GLP-1 for weight loss, people typically regain the weight within two years.

 GLP-1 receptor agonists work by suppressing appetite, slowing digestion, and regulating blood sugar, so when you stop taking them, those effects stop, too.

 The body's hunger signals return, food moves through the stomach faster, and the physiological drive to eat reasserts itself.

“Obesity is a chronic, relapsing disease, and clinical trials have shown that sudden discontinuation of semaglutide or tirzepatide results in weight regain — up to two-thirds of the lost weight within one year — along with reversal of cardiometabolic improvements,” says Silvana Obici, MD, the chief of the division of endocrinology at Stony Brook Medicine and the medical director of the Stony Brook University Hospital Diabetes Center, in Stony Brook, New York.

How Weight Regain Can Affect Type 2 Diabetes

GLP-1 receptor agonists also improve blood glucose through mechanisms beyond weight loss. They also work by boosting insulin secretion and suppressing the levels of glucagon, a hormone that keeps blood sugar levels from falling too low.

This worsening of blood sugar levels after a person stops taking a GLP-1 receptor agonist is not only common; it “is a well-documented phenomenon now termed ‘metabolic rebound,’” says Obici.

Some research has also found that certain cardiometabolic measures, including blood sugar and lipid levels, typically return to their pre–weight loss baselines within about a year and a half after treatment is stopped.

“Once the drug is stopped, that pharmacologic support is immediately removed, allowing blood sugar to rise even in the absence of significant weight regain,” says Obici.

How to Prevent Post-GLP-1 Weight Regain and Keep Your Type 2 Diabetes in Check

“We know that daily physical activity, mindful eating, and a healthy diet help people maintain weight loss in general,” says Norfleet. “But these approaches have not been tested specifically in people who are stopping GLP-1 agonist medications.”

In the meantime, these tips can help you keep weight off after you stop taking a GLP-1.

Exercise Regularly

To keep weight off, try to get 200 to 300 minutes of exercise each week.

 It doesn’t have to be for an hour at a time — it can be a 20-minute walk, a few times a day, for instance.

 Focus, too, on doing resistance training, which helps preserve lean mass and metabolic rate, Norfleet says.

Track Your Weight and Habits

Keeping tabs on your progress can help you spot weight regain before it becomes harder to reverse. This can include tracking body weight, eating patterns, and physical activity on a regular basis.

Eat a Healthy Diet

Diet quality plays a key role in maintaining weight loss over time. Try to eat minimally processed, nutrient-dense foods to stay fuller, longer — a habit that can help keep the weight from gradually creeping back on.

Rethink Your GLP-1 Regimen

Some people may benefit from taking a lower dose of the medication or switching to a different GLP-1 rather than stopping it altogether. “The treatment dose should be individualized to balance weight loss goals, health benefits, and tolerability, and may be less than the maximum approved dose,” says Obici.

“When tapering GLP-1 receptor agonists, clinicians should monitor weight, metabolic health, activity levels, appetite, and muscle strength,” says Obici.

If you’ve stopped taking a GLP-1 for financial reasons, which may include a change in health insurance coverage, you can also look for financial assistance programs from the drug manufacturers that offer the drug for free or at a reduced price.

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Rodriguez PJ et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Network Open. January 31, 2025.
  2. Maureen Salamon. Weaning Off a GLP-1? Tips for the Transition. Harvard Health Publishing. March 16, 2026.
  3. Gonzalez-Rellan MJ. The Expanding Benefits of GLP-Medicines. Cell Reports Medicine. July 16, 2025.
  4. Pidd K et al. Effects of Weight Loss and Weight Gain on Hba1c, Systolic Blood Pressure and Total Cholesterol In Three Subgroups Defined By Blood Glucose: A Pooled Analysis of Two Behavioural Weight Management Trials In England. BMJ Open. April 15, 2025.
  5. Bonekamp NE et al. Effect of Dietary Patterns on Cardiovascular Risk Factors in People with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Research and Clinical Practice. January 2023.
  6. Rasouli N et al. Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial. Diabetes Care. January 11, 2024.
  7. Gusev E et al. Insulin Resistance and Inflammation. International Journal of Molecular Sciences. January 25, 2026.
  8. West S et al. Weight Regain After Cessation of Medication for Weight Management: Systematic Review and Meta-Analysis. TheBMJ. January 7, 2026.
  9. GLP-1 Agonists. Cleveland Clinic. July 3, 2023.
  10. Tzang C-C et al. Metabolic Rebound After GLP-1 Receptor Agonist Discontinuation: A Systematic Review and Meta Analysis. eClinical Medicine. December 2025.
  11. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. January 2, 2024.
  12. Wilding JPH et al. Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The STEP 1 Trial Extension. Diabetes, Obesity and Metabolism. May 19, 2022.
  13. Nadolsky K et al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease - 2025 Update. Endocrine Practice. November 2025.
  14. Tips for Keeping Weight Off. Centers for Disease Control and Prevention. November 15, 2023.
  15. Steps for Losing Weight. Centers for Disease Control and Prevention. January 17, 2025.
  16. Basile AJ et al. Minimally Processed Foods Have a Higher Total Antioxidant Content Compared to Processed and Ultra-Processed Foods: Results From an Analysis of 1946 Food Items. British Journal of Nutrition. November 11, 2024.
Meet Our Experts
See Our Editorial PolicyMeet Our Health Expert Network
Elise-M-Brett-bio

Elise M. Brett, MD

Medical Reviewer
Castle Connolly Top Doctor
Elise M Brett, MD, is a board-certified adult endocrinologist. She received a bachelor's degree from the University of Michigan and her MD degree from the Icahn School of Medicine ...
See full bio

Cathy Garrard

Author
Cathy Garrard is a journalist with more than two decades of experience writing and editing health content. Her work has appeared in print and online for clients such as UnitedHealt...
See full bio
See Our Editorial PolicyMeet Our Health Expert Network